- Home
- QDEL vs ZLAB Comparison
QDEL vs ZLAB Comparison
Compare QDEL & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QDEL | ZLAB |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | QDEL | ZLAB |
|---|---|---|
| Price | $33.07 | $18.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $39.33 | ★ $53.52 |
| AVG Volume (30 Days) | 821.9K | ★ 854.6K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,714,400,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $26.16 |
| Revenue Next Year | $2.42 | $30.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $19.50 | $16.82 |
| 52 Week High | $46.24 | $44.34 |
Technical Indicators
Market Signals| Indicator | QDEL | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 49.39 |
| Support Level | $31.87 | $18.40 |
| Resistance Level | $35.58 | $19.83 |
| Average True Range (ATR) | 1.67 | 0.56 |
| MACD | 0.07 | 0.23 |
| Stochastic Oscillator | 61.04 | 58.11 |
Price Performance
Historical ComparisonAbout QDEL QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.